Teriparatide biosimilar (STADA Arzneimittel AG)

特立帕肽生物类似药(STADA Arzneimittel AG)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameTeriparatide biosimilar (STADA Arzneimittel AG)
Drug Alias Name特立帕肽生物仿制药(STADA Arzneimittel AG)MovymiarhPTH (1-34) (STADA Arzneimittel AG)
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant coagulation factor
Mechanisms of ActionParathyroid hormone replacements
TargetsParathyroid hormone receptor
Therapy Area/IndicationsOsteoporosis
Global Approved IndicationsOsteoporosis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2017/01/11
Country/TerritoryEU
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesStada Arzneimittel Ag
China Registration ClassN/A

Develop Information

Active CompaniesStada Arzneimittel Ag
Inactive CompaniesN/A
Active IndicationsOsteoporosis
Inactive IndicationsN/A

Other Information

ATC CodeH05AA02
Related LinksN/A